Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 2)
- Condition
- Long COVID
- At worst
- Severe (mostly bedbound)
- Ill for
- 8 months
- Published
- Nov 2023
Summary
This patient fell ill with severe long COVID in early 2021, with profound cognitive difficulty and extreme exercise intolerance, and gained only mild relief from vaccination. More than six months later, after testing positive for COVID again, she received the same monoclonal antibody cocktail and the post reports her symptoms disappeared entirely within five days. She was reinfected in summer 2022 but remained healthy two years after the antibody treatment.
What they credit
Credits Craniocervical surgery, Biologics & antibodies, Monoclonal antibodies (casirivimab, Pemgarda).
Similar stories
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Monoclonal antibodies article comments
Credits monoclonal antibody. An unnamed patient was ill 4.5y with severe long COVID, improved, then relapsed. Pemgarda gives 8-10 week remission per dose.
-
Three Long-term Long COVID Patients, Three Rapid Recoveries
Pemivibart (Pemgarda), a monoclonal antibody infusion whose effect the article says typically lasts about a couple of months, was given to three long-term long COVID patients. A 70-year-old woman, sick for nearly a year, had her brain fog, breathlessness and…
-
No easy home runs: early Long COVID Paxlovid and monoclonal trials
Amy Engebretson took part in Yale's PaxLC trial of Paxlovid and has continued taking ritonavir, one of Paxlovid's components, because she says it "improved my symptoms quite a bit"; the article gives no specific dose or treatment duration for her. It does…